Stockreport

Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to earnings of $0 [Read more]